Shamburg News · 8-K filed Oct 27, 2026, 5:25 PM EDT

Aclaris Therapeutics Prices Underwritten Offering of Common Stock and Pre-Funded Warrants

ACRS · Aclaris Therapeutics, Inc.

  • Financing
  • Material agreement
  • Materiality: medium

On October 27, 2026, Aclaris Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co. as representatives of the underwriters for an underwritten offering of 7,785,714 shares of common stock and pre-funded warrants to purchase 6,500,000 shares. The offering price is $3.50 per share of common stock and $3.49999 per pre-funded warrant, with estimated net proceeds of approximately $46.7 million. Closing is expected on October 28, 2026, subject to customary conditions.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 9.01, accession 0001104659-26-119231.

Written from the filing by Shamburg Markets. Figures are as reported by the company.